On June 4, 2019 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, reported that it will participate in two upcoming investor conferences (Press release, Halozyme, JUN 4, 2019, View Source [SID1234536873]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12 at 1:40 p.m. ET / 10:40 a.m. PT in Rancho Palos Verdes, CA. Dr. Helen Torley, president and chief executive officer, will represent the company in a question and answer session.
The JMP Securities Life Sciences Conference on Wednesday, June 19 at 2:30 p.m. ET / 11:30 a.m. PT in New York, NY. Laurie Stelzer, senior vice president and chief financial officer, will represent the company in a question and answer session.
A live webcast of each session can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access a live webcast, please visit Halozyme’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software.